Chinese drug-discovery company using DNA-encoded library technology to find and license small-molecule drug candidates.
Chinese drug-discovery company using DNA-encoded library technology to find and license small-molecule drug candidates.
Charges fees to run screens of its DNA-encoded library against customers' drug targets, and earns milestone payments and possible royalties when partners move compounds it found into development. Fee-for-service work is the steadier part, while milestones are lumpy.
In one line: A Chinese DNA-encoded-library drug discovery specialist.
Moat: narrow (IP / patents, process know-how). One of the few companies globally with a mature, large-scale DNA-encoded library platform.
Headquarters: Chengdu, China · Employees: 546
Size Hitgen (688222.SS) is a China Health Care company (Biotechnology) with a market value of $1.62B, the 1412th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥29.05 on 18 Nov 2026.
Performance Over six months the shares fell 2.8%, against -11.9% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue grew 41.7% over the last twelve months (peer median +23.4%); the operating margin is 26.9% (peer median 3.4%).
Valuation It trades at 73.2× forward earnings against a peer median of 25.1× (most expensive of 9).
Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.6 points above its cost of capital (10.1% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥706M | CN¥526M | CN¥427M | CN¥367M | CN¥330M |
| Revenue growth | — | +23% | +16% | +12% | — |
| Gross profit | CN¥431M | CN¥268M | CN¥198M | CN¥159M | CN¥134M |
| EBITDA | n/a | CN¥167M | CN¥117M | CN¥60.1M | CN¥30.6M |
| Net income | CN¥156M | CN¥110M | CN¥51.4M | CN¥40.7M | CN¥25.3M |
| Free cash flow | CN¥55.4M | CN¥66.3M | CN¥71.2M | CN¥91.4M | -CN¥13.5M |
| Capital expenditure | CN¥184M | CN¥161M | CN¥71.7M | CN¥53.7M | CN¥87.3M |
| Total debt | CN¥430M | CN¥238M | CN¥217M | CN¥236M | CN¥250M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hitgen 688222.SS | $1.62B | -3% | +42% | 27% | 73.2× | 33.2% |
| Wuxi Apptec 2359.HK | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% |
| Pharmaron Beijing 3759.HK | $9.65B | +48% | +24% | 14% | 20.8× | n/a |
| Evotec EVT.DE | $532M | -46% | -5% | -15% | n/a | n/a |
| Viva Biotech 1873.HK | $303M | -18% | +7% | 10% | 8.1× | 2.6% |
| Charles River Laboratories CRL | $16.0B | +114% | -1% | 15% | 26.2× | 25.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688222.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.9% | -7.1% | 3rd lowest of 21 |
| 6-month return | -2.8% | -11.9% | 9th highest of 20 |
| Distance from 52-week high | -38.9% | -44.5% | 9th highest of 21 |
| Revenue growth (TTM) | +41.7% | +23.4% | 7th highest of 19 |
| Operating margin | 26.9% | 3.4% | 4th highest of 19 |
| Forward P/E | 73.2× | 25.1× | most expensive of 9 |
| Growth the price implies (Req g, 7 yrs) | 33.2% | -7.6% | most demanding of 4 |
| Growth delivered (Del g) | +16.8% | +24.8% | 2nd lowest of 4 |
| Hurdle (Req g minus delivered) | +16.4 pp | -27.1 pp | most demanding of 4 |
| ROIC minus cost of capital | +8.6 pp | -5.9 pp | 4th highest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 73.2× | 33.2% | +16.8% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 22.6× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 7.5× | -7.6% | +33.5% |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 27.6× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 52.1× | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 18.1× | -12.1% | +15.0% |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 7.3× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | n/a | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | n/a | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | n/a | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 51.9× | 33.0% | +24.8% |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | n/a | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | 46.4× | n/a | n/a |